Clinical Evidence for
Personalized Heart Attack Prevention
Personalized Cardiac Care Through Science-Based Plaque Analysis
Dr. Andrew Freeman, Director of Cardiovascular Prevention and Wellness at National Jewish Health, and Cleerly founder Dr. James K. Min discuss addressing the root cause of heart disease and personalizing care through science-based plaque analysis.
How Cleerly Compares to Current Heart Disease Testing Methods
Cleerly vs. Level 3 Board Certified Expert Readers
|For severe stenosis >70%, AI-QCT performance was excellent for measures of accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)|
Cleery is superior to the consensus of Level 3 Expert Readers in determining stenosis severity, plaque volume and composition.1
Cleerly vs. Quantitative Coronary Angiography (QCA)
Per-patient AI-QCT performance for severe stenosis >70%
|Accuracy||86%||In cases where quantitative invasive angiography and AI-QCT disagreed, Ai-QCT exhibited higher agreement with invasive FFR for coronary ischemia, with more than 2/3 vessels considered ischemic by invasive FFR.
Cleerly demonstrates high diagnostic performance for determining stenosis severity.2
Cleerly vs. Myocardial Perfusion Imaging
Cleerly demonstrates higher diagnostic performance than myocardial perfusion imaging (MPI) for detecting obstructive CAD.3
Cleerly vs. Intravascular Ultrasound
|Vessel Area (mm2)||0.63|
|Lumen Area (mm2)||0.43|
|Plaque Area (mm2)||0.52|
|MLA per artery (mm2)||0.67|
Cleerly demonstrates high agreement with intravascular ultrasound (IVUS) for absolute measures of coronary lumen size to determine accurate stenoses measurements.4
Cleerly vs. Near Field Infrared Spectroscopy
|Positive Predictive Value||81%|
|Negative Predictive Value||98%|
Cleerly demonstrates high agreement with near field infrared spectroscopy (NIRS) for the identification of lipid-rich plaques.5
Cleerly Reduces Expensive and Invasive Testing Methods
Coronary computed tomography angiography (CCTA) is a noninvasive diagnostic method that is shown to be highly effective at identifying arterial plaque when used in tandem with Cleerly. This can make it an effective precursor to more invasive testing methods.
1 CT Evaluation by Artificial Intelligence for Atherosclerosis, Stenosis and Vascular Morphology. Journal of Cardiovascular Computed Tomography. Published November 2022.
2 AI Evaluation of Stenosis on Coronary CT Angiography, Comparison with Quantitative Coronary Angiography and Fractional Flow Reserve. Journal of the American College of Cardiology. Published February 2022.
3 Coronary CTA with AI-ACT Interpretation: Comparison with Myocardial Perfusion Imaging for Detection of Obstructive Stenosis Using Invasive Angiography as Reference Standard. American Journal of Roentgenology. Published September 2022.
4 Comparison of Endothelial Shear Stress Computation Utilizing Non-invasive Coronary Computed Tomography Angiography vs Invasive Intravascular Ultrasound Imaging, Hakin D et al, JCCT In Press 2022.
5 Omori et al AHA 2022.
6 Yukim Kim et al. In Submission. ESC Imaging 2022.
7 Coronary CTA Plaque Volume Severity Stages According to Invasive Coronary Angiography and FFR. Journal of Cardiovascular Computed Tomography. Published March 2022.
8 Coronary Atherosclerotic Precursors of Acute Coronary Syndromes. Journal of the American College of Cardiology. Published June 2018.
9 Progression of Atherosclerotic Plaque DetermIned by Computed TomoGraphic Angiography Imaging [PARADIGM]. Journal of the American College of Cardiovascular Imaging. Last Updated 2018.
10 Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. New England Journal of Medicine. Released September 2018.
Have questions about Cleerly’s clinical evidence?
Contact us for more information on Cleerly-led clinical studies, randomized controlled trials, and external research initiatives.